• 06 Jan 2026
• Admin
• News Article

TempraMed Expands South Korea Footprint With New Commercial Order

TempraMed Technologies has announced a new commercial order and an extended distribution partnership in South Korea.

The move strengthens its presence in one of Asia’s fastest-growing injectable drug markets.

Expanded Partnership With Mavens

The agreement extends TempraMed’s collaboration with Mavericks Co. Ltd (Mavens), a South Korea–based healthcare distributor.

Key highlights:

• Builds on an existing commercial relationship
• Follows the granting of a South Korean patent for TempraMed’s thermal insulation technology
• Expands access across pharmacies, hospitals, clinics, and patient communities

Mavens brings deep local networks across the South Korean healthcare ecosystem.

Why South Korea Matters?

South Korea is emerging as a high-growth market for injectable therapies.

Market context:

• One of Asia’s largest pharmaceutical markets
• Strong growth expected over the next decade
• Diabetes drugs market valued at ~US$1 billion
• Rising demand for insulin, GLP-1s, biologics, and emergency injectables

An aging population and lifestyle shifts are driving sustained demand.

The Temperature-Sensitivity Problem

Many injectable drugs are highly temperature sensitive.

Exposure risks include:

• Loss of potency from heat or cold
• Reduced treatment effectiveness
• Increased risk of therapy failure

As injectables move beyond clinics into daily life, passive thermal protection becomes critical.

What TempraMed Brings to the Table?

TempraMed develops battery-free thermal protection devices for medications.

Its solutions:

• Protect insulin, GLP-1s, biologics, and emergency injectables
• Use patented, space-grade insulation
• Operate 24/7 without external power

Recent launches include the VIVI Cap Smart device.

Executive Perspectives

Chang Gyu An, CEO of Mavens, said the partnership addresses real patient needs:

• Practical solutions matter for injectable medication users
• The expanded agreement builds on strong market momentum

Ron Nagar, CEO of TempraMed, highlighted timing and demand:

• Injectable medication use is rising rapidly in South Korea
• The new patent and stronger local presence support faster adoption

Part of a Broader Global Strategy

The South Korea expansion follows recent distribution agreements across:

• Turkey
• Israel
• Multiple European markets

Together, these deals signal accelerating global growth.

Bottom Line

TempraMed is positioning itself at the intersection of:

• Rising injectable drug use
• Growing patient self-administration
• Increasing need for reliable temperature protection

South Korea is now a key pillar in that global expansion strategy.